A population-based seroprevalence survey of severe acute respiratory syndrome coronavirus 2 infection in Beijing, China

BACKGOUND The spread of Coronavirus Disease 2019 (COVID-19) had been controlled in China. The seroprevalence of COVID-19 in Beijing has not been evaluated. METHODS In April, residents in Beijing were randomly enrolled. Blood samples were collected and antibodies to SARS-CoV-2 were tested by two colloidal gold kits. All colloidal gold positive serums were then tested by Micro-neutralization assay. RESULTS None of 2,184 residents participated was tested positive by micro-neutralization assay. The seroprevalence of COVID-19 in Beijing was estimated < 0.17%. CONCLUSIONS The seroprevalence of COVID-19 was low in April suggesting that community-wide spread was prevented in Beijing.